» Articles » PMID: 29740894

Epidemiology of Prostate Cancer in Asian Countries

Overview
Journal Int J Urol
Specialty Urology
Date 2018 May 10
PMID 29740894
Citations 177
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence of prostate cancer has been increasing worldwide in recent years. The GLOBOCAN project showed that prostate cancer was the second most frequently diagnosed cancer and the fifth leading cause of cancer mortality among men worldwide in 2012. This trend has been growing even in Asian countries, where the incidence had previously been low. However, the accuracy of data about incidence and mortality as a result of prostate cancer in some Asian countries is limited. The cause of this increasing trend is multifactorial. One possible explanation is changes in lifestyles due to more Westernized diets. The incidence is also statistically biased by the wide implementation of early detection systems and the accuracy of national cancer registration systems, which are still immature in most Asian countries. Mortality rate decreases in Australia, New Zealand and Japan since the 1990s are possibly due to the improvements in treatment and/or early detection efforts employed. However, this rate is increasing in the majority of other Asian countries. Studies of latent and incidental prostate cancer provide less biased information. The prevalence of latent and incidental prostate cancer in contemporary Japan and Korea is similar to those in Western countries, suggesting the influence of lifestyle changes on carcinogenesis. Many studies reported evidence of both congenital and acquired risk factors for carcinogenesis of prostate cancer. Recent changes in the acquired risk factors might be associated with the increasing occurrence of prostate cancer in Asian countries. This trend could continue, especially in developing Asian countries.

Citing Articles

Primary management of prostate cancer by universal health coverage effective coverage index.

Blas L, Shiota M, Onozawa M, Joung J, Koo K, Turkeri L World J Urol. 2025; 43(1):146.

PMID: 40032670 DOI: 10.1007/s00345-025-05530-7.


Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan.

Kimura T, Takahashi N, Asakawa K, Saito A, Mitomi T, Lee T Oncol Ther. 2025; 13(1):217-232.

PMID: 39921822 PMC: 11880441. DOI: 10.1007/s40487-025-00326-6.


Human immune system: Exploring diversity across individuals and populations.

Hoang Nguyen K, Le N, Nguyen P, Nguyen H, Hoang D, Huynh C Heliyon. 2025; 11(2):e41836.

PMID: 39911431 PMC: 11795082. DOI: 10.1016/j.heliyon.2025.e41836.


Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N Int J Clin Oncol. 2024; 30(3):551-558.

PMID: 39688742 DOI: 10.1007/s10147-024-02681-2.


Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer.

Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T Cancer Med. 2024; 13(24):e70226.

PMID: 39676240 PMC: 11646809. DOI: 10.1002/cam4.70226.